TENX RSI Chart
Last 7 days
-1.1%
Last 30 days
-1.1%
Last 90 days
-14.5%
Trailing 12 Months
-85.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 7.0M | 9.3M | 11.6M | 13.9M |
2015 | 0 | 49.3K | 4.7M | 0 |
2014 | 444.9K | 263.0K | 0 | 0 |
2013 | 1.1M | 1.2M | 1.1M | 625.5K |
2012 | 346.3K | 381.1K | 593.7K | 1.0M |
2011 | 0 | 104.1K | 156.6K | 224.7K |
2010 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Sep 21, 2022 | rich stuart | gifted | - | - | 1,909,580 | chief medical officer |
Sep 21, 2022 | rich stuart | gifted | - | - | -1,909,580 | chief medical officer |
Aug 11, 2022 | doogan declan | gifted | - | - | -567,871 | - |
Aug 11, 2022 | doogan declan | gifted | - | - | 567,871 | - |
Nov 29, 2021 | rich stuart | gifted | - | - | 1,909,580 | chief medical officer |
Nov 29, 2021 | rich stuart | gifted | - | - | -1,909,580 | chief medical officer |
Oct 12, 2021 | rich stuart | gifted | - | - | 1,909,580 | chief medical officer |
Oct 12, 2021 | rich stuart | gifted | - | - | -1,909,580 | chief medical officer |
Jun 30, 2021 | doogan declan | gifted | - | - | -567,871 | - |
Jun 11, 2021 | davidson michael h. | acquired | - | - | 512,000 | - |
Which funds bought or sold TENX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | STATE STREET CORP | sold off | -100 | -26,105 | - | -% |
May 15, 2024 | MORGAN STANLEY | sold off | -100 | -5,678 | - | -% |
May 15, 2024 | MORGAN STANLEY | new | - | 1,102 | 1,102 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | sold off | -100 | -1,253 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | new | - | 2,277 | 2,277 | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | sold off | -100 | -39,095 | - | -% |
May 15, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -13,883 | - | -% |
May 14, 2024 | Qube Research & Technologies Ltd | sold off | -100 | -137 | - | -% |
May 14, 2024 | Qube Research & Technologies Ltd | new | - | 18,686 | 18,686 | -% |
May 13, 2024 | RENAISSANCE TECHNOLOGIES LLC | sold off | -100 | -93,000 | - | -% |
Unveiling Tenax Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Tenax Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Tenax Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2015Q3 | 2015Q2 | 2015Q2 | 2014Q2 | 2014Q1 | 2013Q4 | 2013Q3 | 2013Q2 | 2013Q1 | 2012Q4 | 2012Q3 | 2012Q2 | 2012Q1 | 2011Q4 | 2011Q3 | 2011Q2 | 2011Q1 |
Revenue | -0.9% | 13,530 | 13,652 | 13,774 | 13,897 | 11,126 | 8,355 | 5,584 | 2,813 | 42.00 | 56.00 | 166 | 182 | 222 | 515 | 272 | 78.00 | 148 | 95.00 | 59.00 | 43.00 | 27.00 |
Gross Profit | - | - | - | - | - | - | - | - | -133 | 180* | 21.00 | 8.00 | 37.00 | 1.00 | 5.00 | 6.00 | 5.00 | 2.00 | 17.00 | 25.00 | 44.00 | 27.00 |
Operating Expenses | 57.8% | 3,341 | 2,117 | 1,236 | 1,539 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
S&GA Expenses | 56.1% | 1,642 | 1,052 | 1,038 | 1,274 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
R&D Expenses | 59.4% | 1,699 | 1,066 | 198 | 266 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | -59.6% | 2.00 | 5.00 | 9.00 | 7.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | 191.0% | 5,739 | 1,972 | -1,106 | -1,406 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income Margin | -42.9% | 0.37* | 0.65* | 0.92* | 0.97* | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | 43.6% | -1,174 | -2,082 | -924 | -1,726 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 23.8% | 14,460 | 11,685 | 11,889 | 14,045 | 15,272 | 3,405 | 4,739 | 8,355 | 3,738 | 5,992 | 8,912 | 2,885 | 4,561 | 6,869 | 8,997 | 5,353 | 5,955 | 6,365 | 7,774 | 9,664 | 11,457 |
Current Assets | 23.8% | 14,459 | 11,684 | 11,883 | 14,039 | 15,265 | 3,208 | 4,514 | 8,102 | 3,456 | 5,689 | 8,583 | 2,532 | 4,518 | 6,796 | 8,897 | 5,214 | 5,798 | 6,181 | 7,562 | 9,425 | 11,191 |
Cash Equivalents | 28.2% | 12,549 | 9,792 | 11,141 | 13,394 | 14,415 | 2,124 | 3,806 | 7,229 | 2,869 | 5,584 | 8,354 | 1,671 | 3,537 | 6,250 | 8,236 | 4,085 | 4,359 | 4,906 | 6,649 | 8,407 | 10,322 |
Net PPE | - | - | - | 5.00 | 6.00 | 6.00 | 7.00 | 10.00 | 11.00 | 12.00 | 7.00 | 6.00 | 6.00 | 5.00 | 6.00 | 3.00 | 4.00 | 5.00 | 7.00 | 8.00 | 9.00 | 10.00 |
Liabilities | -43.4% | 2,031 | 3,587 | 602 | 824 | 989 | 1,912 | 785 | 1,572 | 2,131 | 1,748 | 1,673 | 1,414 | 1,465 | 2,243 | 1,593 | 2,324 | 2,536 | 2,593 | 1,237 | 1,044 | 1,117 |
Current Liabilities | -43.4% | 2,031 | 3,587 | 602 | 824 | 984 | 1,848 | 690 | 1,446 | 1,976 | 1,564 | 1,461 | 1,175 | 1,434 | 2,119 | 1,379 | 2,187 | 2,505 | 2,532 | 1,129 | 938 | 1,014 |
Shareholder's Equity | 53.5% | 12,430 | 8,098 | 11,287 | 13,222 | 14,278 | 1,493 | 3,954 | 6,784 | 1,606 | 4,245 | 7,239 | 1,471 | 3,096 | 4,626 | 7,404 | 3,029 | 3,419 | 3,772 | 6,537 | 10,340 | 10,340 |
Retained Earnings | -1.3% | -301,051 | -297,252 | -294,027 | -292,055 | -290,948 | -289,542 | -286,993 | -284,076 | -281,215 | -278,494 | -275,283 | -271,484 | -269,767 | -246,019 | -243,190 | -240,969 | -238,823 | -236,168 | -233,376 | -231,153 | -229,391 |
Additional Paid-In Capital | 2.7% | 313,481 | 305,351 | 305,311 | 305,274 | 305,224 | 291,035 | 290,944 | 290,858 | 282,819 | 282,736 | 282,520 | 272,954 | 272,863 | 250,644 | 250,592 | 243,996 | 242,242 | 239,940 | 239,911 | 239,771 | 239,729 |
Shares Outstanding | - | 1,958 | - | 23,862 | 23,862 | 21,777 | - | 29,980 | 1,260 | 1,260 | 1,260 | 1,260 | 1,261 | 748 | 12,619 | - | - | - | - | - | - | - |
Float | - | - | - | - | 7,031 | - | - | - | 5,005 | - | - | - | 30,559 | - | - | - | 9,100 | - | - | - | 9,167 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 43.6% | -1,174 | -2,081 | -922 | -1,724 | -1,688 | -3,330 | -3,431 | -2,937 | -2,768 | -3,021 | -1,845 | -3,221 | -1,987 | -2,385 | -2,228 | -2,671 | -1,726 | -1,782 | -1,914 | -2,132 | -1,197 |
Share Based Compensation | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 53.00 |
Cashflow From Investing | - | - | - | 2.00 | 1.00 | 4.00 | - | - | -6.32 | -1.70 | 512 | -20.27 | -36.96 | 4.00 | 3.00 | 20.00 | -6.33 | -16.75 | 24.00 | -204* | -8.80 | 1,311 |
Cashflow From Financing | -1.9% | -174 | -171 | -99.91 | 14,015 | 2.00 | -91.87 | 7,792 | 229 | - | 9,193 | - | 545 | -1.35 | 6,533 | 1,935 | 2,130 | - | - | - | 97.00 | 8,907 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses | ||
General and administrative | $ 1,232,674 | $ 1,273,730 |
Research and development | 2,675,652 | 265,735 |
Total operating expenses | 3,908,326 | 1,539,465 |
Net operating loss | 3,908,326 | 1,539,465 |
Interest expense | 7,963 | 7,350 |
Other expense (income), net | (117,449) | (140,055) |
Net loss | $ 3,798,840 | $ 1,406,760 |
Net loss per share, basic and diluted | $ (3.12) | $ (12.10) |
Weighted average number of common shares outstanding, basic and diluted | 1,219,139 | 116,259 |
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Cash and cash equivalents | $ 12,549,475 | $ 9,792,130 |
Prepaid expenses | 1,843,047 | 1,639,797 |
Other current assets | 66,625 | 251,583 |
Total current assets | 14,459,147 | 11,683,510 |
Other assets | 1,117 | 1,117 |
Total assets | 14,460,264 | 11,684,627 |
Accounts payable | 1,080,962 | 2,073,149 |
Accrued liabilities | 536,443 | 1,012,468 |
Note Payable | 413,174 | 500,903 |
Total current liabilities | 2,030,579 | 3,586,520 |
Total liabilities | 2,030,579 | 3,586,520 |
Common stock, par value $.0001 per share; authorized 400,000,000 shares; issued and outstanding 1,958,245 as of March 31, 2024 and 298,281 as of December 31, 2023, respectively | 0 | 0 |
Additional paid-in capital | 313,481,082 | 305,350,830 |
Accumulated deficit | (301,051,593) | (297,252,753) |
Total stockholders' equity | 12,429,685 | 8,098,107 |
Total liabilities and stockholders' equity | 14,460,264 | 11,684,627 |
Series A Preferred Stock [Member] | ||
Series A Preferred stock, par value $.0001, authorized 5,181,346 shares; issued and outstanding 210, as of March 31, 2024 and December 31, 2023, respectively | $ 196 | $ 30 |